Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers

Butt, Adeel A.; Khan, Uzma; Shaikh, Obaid S.; McMahon, Deborah; Dorey-Stein, Z.; Tsevat, Joel; Re, Vincent Lo

doi:10.1310/hct1001-25

Cited by 27 publications

(13 citation statements)

References 27 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subjects were defined as having diabetes if any of the following criteria were met: (i) glucose ≥ 200 mg/dL on two separate occasions; (ii) International Classification of Diseases, Ninth Revision (ICD-9) codes (two or more outpatient or one or more inpatient) plus treatment with insulin or an oral hypoglycaemic for 30 days or more; (iii) ICD-9 codes (two outpatient or one inpatient) plus glucose ≥ 126 mg/dL on two separate occasions; and (iv) glucose ≥ 200 mg/dL on one occasion plus treatment with insulin or an oral hypoglycaemic for 30 days or more. 20,21 History of alcohol dependence or abuse, history of drug dependence or abuse and hypertension were determined according to ICD-9 codes (at least two outpatient or one inpatient). 22 Diagnosis of HCC was identified according to the presence of one inpatient or two outpatient ICD-9 diagnoses.…”

Section: Definitionsmentioning

confidence: 99%

Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C‐infected persons: Results from ERCHIVES

Chen

Ren²,

Yan³

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Recent preclinical studies have suggested an antifibrotic role for tricyclic antidepressants (TCA). Using the Electronically Retrieved Cohort of hepatitis C virus (HCV) Infected Veterans, we aimed to evaluate the impact of TCA use on fibrosis progression and development of hepatocellular carcinoma (HCC) among HCV-infected persons. Subjects were categorized according to use of TCAs, selective serotonin reuptake inhibitors (SSRI) or no antidepressants. TCAs or selective serotonin uptake inhibitors use was defined according to cumulative defined daily dose (cDDD), and categories were mutually exclusive. Subjects with HIV coinfection, hepatitis B surface antigen (HbsAg) positivity, cirrhosis or HCC at baseline were excluded. Outcomes were liver fibrosis progression measured by APRI scores and incident HCC. We utilized Cox proportional hazards regression to determine predictors of cirrhosis, defined as APRI > 2, and incident hepatocellular carcinoma (iHCC). Among 128 201 eligible HCV+ persons, 4% received TCAs, 43% received selective serotonin uptake inhibitors, and 53% received no antidepressants. Fewer TCAs users had drug abuse (34% and 43%) and alcohol abuse (32% vs 42%) compared to selective serotonin uptake inhibitor users. After adjusting for age, baseline APRI score, diabetes, hypertension, alcohol use, drug abuse and HCV RNA levels, TCAs use was associated with decreased risk of cirrhosis (hazard ratio [HR] = 0.77, 95% CI = 0.60, 0.99) and delayed time to development of cirrhosis, but not with decreased iHCC. In conclusion among a large cohort of HCV-positive Veterans, TCAs use was associated with decreased fibrosis progression and lower risk of developing cirrhosis. These data provide supportive evidence for the beneficial effects of TCAs on progression of liver fibrosis in patients with chronic HCV infection.

show abstract

Section: Definitionsmentioning

confidence: 99%

Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C‐infected persons: Results from ERCHIVES

Chen

Ren²,

Yan³

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…We also retrieved information on prescriptions of erythropoiesis-stimulating agents (ESA; erythropoietin and darbopoietin) and HMG-CoA reductase inhibitors (statins). Subjects were considered to have diabetes if they met any of the following criteria: (i) Glucose >200 mg/dl on two separate occasions; (ii) ICD-9 codes (two or more outpatient OR one or more inpatient) PLUS treatment with an oral hypoglycaemic or insulin for >30 days; (iii) ICD-9 codes (two outpatient OR one inpatient) PLUS glucose >126 mg/dl on two separate occasions; (iv) Glucose > 200 mg/dl on one occasion PLUS treatment with an oral hypoglycaemic or insulin for >30 days (19). Chronic kidney disease definition was based on two estimated glomerular filtration rate values at least 90 days apart calculated using the CKD-EPI equation (13).…”

Section: Data Collection and Definitionsmentioning

confidence: 99%

Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES

Butt

Yan

Shaikh

et al. 2015

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…We also retrieved information on prescriptions of erythropoiesis-stimulating agents (ESA, erythropoietin and darbopoietin) and HMG-CoA reductase inhibitors (statins). Subjects were considered to have diabetes if they met any of the following criteria: (i) glucose ≥200 mg/dL on two separate occasions; (ii) ICD-9 codes (two or more outpatient OR one or more inpatient) PLUS treatment with an oral hypoglycaemic or insulin for ≥30 days; (iii) ICD-9 codes (two outpatient OR one inpatient) PLUS glucose ≥126 mg/dL on two separate occasions; and (iv) glucose ≥200 mg/dL on one occasion PLUS treatment with an oral hypoglycaemic or insulin for ≥30 days [19].…”

Section: Data Collectionmentioning

confidence: 99%

Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings

Butt

Yan

Shaikh

et al. 2014

Journal of Viral Hepatitis

View full text Add to dashboard Cite

SUMMARY Effectiveness, safety and tolerability of boceprevir (BOC) and telaprevir (TPV) in actual clinical settings remain unknown. We determined rates of sustained virologic response (SVR) and haematologic adverse effects among persons treated with BOC- or TPV-containing regimens, compared with pegylated interferon/ribavirin (PEG/RBV). Using an established cohort of hepatitis C virus (HCV)-infected persons, Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), we identified those treated with a BOC- or TPV-containing regimen and HCV genotype 1-infected controls treated with PEG/RBV. We excluded those with HIV co-infection and missing HCV RNA values to determine SVR. Primary endpoints were SVR (undetectable HCV RNA ≥12 weeks after treatment completion) and haematologic toxicity (grade 3/4 anaemia, neutropenia and thrombocytopenia). We evaluated 2288 persons on BOC-, 409 on TPV-containing regimen and 6308 on PEG/RBV. Among these groups, respectively, 31%, 43% and 9% were treatment-experienced; 17%, 37% and 14% had baseline cirrhosis; 63%, 54% and 48% were genotype 1a. SVR rates among noncirrhotics were as follows: treatment naïve: 65% (BOC), 67% (TPV) and 31% (PEG/RBV); treatment experienced: 57% (BOC), 54% (TPV) and 13% (PEG/RBV); (P-value not significant for BOC vs TPV; P < 0.0001 for BOC or TPV vs PEG/RBV). Haematologic toxicities among BOC-, TPV- and PEG/RBV-treated groups were as follows: grade 3/4 anaemia 7%, 11% and 3%; grade 4 thrombocytopenia 2.2%, 5.4% and 1.7%; grade 4 neutropenia 8.2%, 5.6% and 3.4%. SVR rates are higher and closer to those reported in pivotal clinical trials among BOC- and TPV-treated persons compared with PEG/RBV-treated persons. Haematologic adverse events are frequent, but severe toxicity is uncommon.

show abstract

Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers

Cited by 27 publications

References 27 publications

Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C‐infected persons: Results from ERCHIVES

Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C‐infected persons: Results from ERCHIVES

Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES

Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings

Contact Info

Product

Resources

About